The Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium, prospectively recruited deeply-phenotyped discovery and refinement psoriasis patient cohorts, during the early phase of treatment with two distinct biologics, adalimumab (TNF inhibitor) and ustekinumab (IL-12/23 inhibitor)...
To identify novel susceptibility loci for psoriasis, we undertook a genome-wide association scan of of 594,224 SNPs in 2,622 individuals with psoriasis and 5,667 controls.
